The earliest date that a generic version of Ventolin could become available is October 2015, when the patent for Ventolin expires. However, there are other circumstances that could come up to extend that date past October 2015, including other patents for specific uses of the medication or lawsuits. Because older, "traditional" albuterol inhalers will no longer be available after December 31, 2008, you should be sure to talk with your healthcare provider if you need help in affording the newer inhalers, such as Ventolin.
Ventolin HFA® (albuterol inhaler) is a prescription medication used to treat asthma and other similar lung problems. It is part of a class of asthma drugs known as beta-adrenergic receptor agonists, or beta agonists for short.
Ventolin is manufactured by GlaxoSmithKline. It is currently under the protection of a patent that prevents any generic Ventolin from being manufactured in the United States. Ventolin is one of only a few environmentally friendly albuterol inhalers. Older, "traditional" albuterol inhalers will no longer be available after December 31, 2008. None of the new inhalers have generic equivalents at this time.
The first patent for Ventolin currently expires in October 2015. Although this patent originally was set to expire in April 2015, the manufacturer was given an extension for performing much-needed pediatric studies.
October 2015 is the earliest predictable date that a generic version of Ventolin could become available. However, there are other circumstances that could arise to extend the exclusivity period of Ventolin beyond 2015. These circumstances could include things such as other patents for specific Ventolin uses or lawsuits. Once Ventolin goes off patent, there may be several companies that manufacture a generic Ventolin drug.